TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34523717

Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction
Number of subjects: 942

Group type: COMPARATOR
Intervention: Billroth-I reconstruction
Number of subjects: 942
Study: 34523725

Group type: EXPERIMENTAL
Intervention: Drinks per drinking day (DPDD)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Middle frontal gyrus (MFG) thickness
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: NfL
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 182
Study: 34523741

Group type: EXPERIMENTAL
Intervention: Isolated diastolic hypertension (IDH)
Number of subjects: 1605
Study: 34524020

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34524092

Group type: EXPERIMENTAL
Intervention: BRAVE SMS text messages
Number of subjects: 833

Group type: COMPARATOR
Intervention: STEM SMS text messages
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: BRAVE SMS text messages after STEM intervention
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: SMS text messages for self-help
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: SMS text messages for helping friends/family
Number of subjects: 833
Study: 34524220

Group type: EXPERIMENTAL
Intervention: High-dose interferon α-2b (HD-IFN)
Number of subjects: 56
Study: 34524263

Group type: EXPERIMENTAL
Intervention: Patients with FD
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 35
Study: 34524647

Group type: EXPERIMENTAL
Intervention: Procalcitonin < 0.1 ng/mL
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Number of positive blood culture bottles ≤ 2
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Non-infection-related admission
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Percentage of positive blood culture bottles ≤ 25%
Number of subjects: 154
Study: 34525188

Group type: EXPERIMENTAL
Intervention: Immunosuppression and eltrombopag (EPAG)
Number of subjects: 178
Study: 34525286

Group type: EXPERIMENTAL
Intervention: 1 mg vaccine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 mg vaccine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postvaccination serum
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baseline serum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 mg and 2 mg vaccines
Number of subjects: 40
Study: 34525979

Group type: EXPERIMENTAL
Intervention: Assistive technology and telecare (ATT) devices
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Tracking devices
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Everyday technology
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Access to ATT for PwDs with severe dementia
Number of subjects: 276
Study: 34526044

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg d1, every 3 weeks, until disease progression, unacceptable toxicity, or up to 35 cycles) + SBRT (8 Gy × 3) + GM-CSF (125 μg/m)
Number of subjects: 20
Study: 34526058

Group type: EXPERIMENTAL
Intervention: Home-based self-help telerehabilitation program assisted by EMG-driven WH-ENMS
Number of subjects: 11
Study: 34526151

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy (G-CBT) for 3 months
Number of subjects: 78

Group type: COMPARATOR
Intervention: Individual Outpatient Treatment (IOT) for 3 months
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy (G-CBT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Individual Outpatient Treatment (IOT)
Number of subjects: 78
Study: 34526343

Group type: EXPERIMENTAL
Intervention: Functional mobility assessments using Performance Oriented Mobility Assessment, Timed Up and Go, and Timed Up and Go dual task
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Monthly self-report of falls (including number and severity) confirmed through interviews
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments and neuroimaging (including molecular imaging using positron emission tomography and MRI)
Number of subjects: 350
Study: 34526804

Group type: EXPERIMENTAL
Intervention: iota-carrageenan containing lozenge
Number of subjects: 31
Study: 34527321

Group type: EXPERIMENTAL
Intervention: COPD patients (n=38)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-COPD smokers (n=38)
Number of subjects: 76
Study: 34527608

Group type: EXPERIMENTAL
Intervention: Sorafenib followed by yttrium 90 glass microspheres
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination therapy (sorafenib followed by yttrium 90 glass microspheres)
Number of subjects: 38
Study: 34527722

Group type: EXPERIMENTAL
Intervention: COPD patients (GOLD Grades I-IV)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: COPD patients (sub-cohort of 400)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Never-smoker healthy controls
Number of subjects: 2000
Study: 34527982

Group type: EXPERIMENTAL
Intervention: Active referral plus a small financial incentive (HK$300/US$38) after using cessation services within 3 months.
Number of subjects: 1093

Group type: COMPARATOR
Intervention: General brief cessation advice (control group).
Number of subjects: 1093
Study: 34528245

Group type: COMPARATOR
Intervention: Norethisterone (24 participants)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Progesterone 600 mg/day (168 participants)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Pooled progesterone RCTs
Number of subjects: 192
Study: 34528308

Group type: COMPARATOR
Intervention: Dietary Inflammatory Index (DII)
Number of subjects: 415
Study: 34528401

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34528591

Group type: EXPERIMENTAL
Intervention: MPFF
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: MPFF + compression
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: MPFF + compression + topical treatment
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: MPFF + compression + topical treatment + endovasal laser coagulation
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: MPFF + endovasal laser coagulation
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: MPFF + compression + endovasal laser coagulation
Number of subjects: 687

Group type: COMPARATOR
Intervention: Patients not receiving MPFF
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Patients receiving topical treatment
Number of subjects: 687

Group type: COMPARATOR
Intervention: Patients not receiving compression therapy
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Patients receiving compression therapy
Number of subjects: 687
Study: 34528763

Group type: EXPERIMENTAL
Intervention: Poziotinib 12 mg orally once daily for 28-day cycle
Number of subjects: 49
Study: 34528857

Group type: EXPERIMENTAL
Intervention: LNG-IUS 12
Number of subjects: 1129
Study: 34528885

Group type: EXPERIMENTAL
Intervention: personalized communication using an mHealth app in addition to standard of care phone communication
Number of subjects: 400

Group type: COMPARATOR
Intervention: standard of care communication only
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: not available
Number of subjects: 400
Study: 34529005

Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET imaging scan (3 to 7 mCi)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET imaging scan
Number of subjects: 764
Study: 34529078

Group type: EXPERIMENTAL
Intervention: PODCI
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PODCI expectations scale
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: GMFM
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: GMFCS
Number of subjects: 108
Study: 34529182

Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin analogues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled epoprostenol (VPCOVID [NCT04452669])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iloprost (ILOCOVID [NCT04445246])
Number of subjects: 0
Study: 34529226

Group type: EXPERIMENTAL
Intervention: Long-term hydroxychloroquine (HCQ) intake
Number of subjects: 569

Group type: COMPARATOR
Intervention: No antirheumatic drug intake
Number of subjects: 569
Study: 34529255

Group type: EXPERIMENTAL
Intervention: Antibiotics initiated for presumed bacterial respiratory tract co-/superinfection
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Drivers of antibiotic prescribing
Number of subjects: 281
Study: 34529313

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34529762

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (2 doses)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: AZD1222 vaccine (1 dose)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Healthy controls (212 patients, 46% men; median age, 66 years)
Number of subjects: 106
Study: 34529930

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) with dosing of 54 Gy in three fractions for peripheral lesions or 50 Gy in four fractions for central tumours (totaling 60 Gy).
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND)
Number of subjects: 80
Study: 34529955

Group type: EXPERIMENTAL
Intervention: Indatuximab ravtansine plus lenalidomide
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Indatuximab ravtansine plus pomalidomide
Number of subjects: 64
Study: 34529983

Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault creatinine clearance (C-G)
Number of subjects: 3985
Study: 34530387

Group type: EXPERIMENTAL
Intervention: Two-week therapeutic anticoagulation (enoxaparin or rivaroxaban)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Six-week anticoagulation (control group)
Number of subjects: 241
Study: 34530728

Group type: EXPERIMENTAL
Intervention: Psychotropic drug prescriptions (PTDs)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Antipsychotic prescriptions
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Sedatives/hypnotics prescriptions
Number of subjects: 696
Study: 34530733

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment initiation
Number of subjects: 111
Study: 34530744

Group type: EXPERIMENTAL
Intervention: Treatment for COVID-19 patients
Number of subjects: 0
Study: 34530760

Group type: EXPERIMENTAL
Intervention: Pyrotinib 400 mg once daily and thalidomide 200 mg once daily until disease progression or intolerable toxicity
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pyrotinib 400 mg once daily and thalidomide 200 mg once daily
Number of subjects: 39
Study: 34530793

Group type: EXPERIMENTAL
Intervention: Internal fixation treatment for lower limb fractures
Number of subjects: 204
Study: 34530834

Group type: EXPERIMENTAL
Intervention: JUUL-brand electronic cigarettes for 6 weeks
Number of subjects: 114
Study: 34530933

Group type: EXPERIMENTAL
Intervention: Supportive care CPG implementation facilitators
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Supportive care CPG implementation barriers
Number of subjects: 35
Study: 34531196

Group type: EXPERIMENTAL
Intervention: NICE NG51 CPG
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: NICE NG143 CPG
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: BSAC CPG
Number of subjects: 555
Study: 34531244

Group type: EXPERIMENTAL
Intervention: Abnl-GT-β-cell failure
Number of subjects: 486

Group type: COMPARATOR
Intervention: Abnl-GT-IR
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Overall prevalence of Abnl-GT
Number of subjects: 486
Study: 34531249

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg on day 1 and carboplatin AUC 2 on days 8 and 15 of a 3-week cycle until progression
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pembrolizumab with carboplatin
Number of subjects: 29
Study: 34531242

Group type: EXPERIMENTAL
Intervention: Monophasic glucose response curve
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: Biphasic glucose response curve
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: Continuous rise glucose response curve
Number of subjects: 3108
Study: 34531250

Group type: EXPERIMENTAL
Intervention: CD33-directed chimeric antigen receptor T cell immunotherapy (CD33CARTs) with CD28 costimulatory domain
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD33-directed chimeric antigen receptor T cell immunotherapy (CD33CARTs) with 4-1BB costimulatory domain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemtuzumab-based CD33CARTs
Number of subjects: 0
Study: 34531264

Group type: EXPERIMENTAL
Intervention: Fluorescent tracer cetuximab-800CW
Number of subjects: 0
Study: 34531279

Group type: COMPARATOR
Intervention: Low dose potassium treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High dose potassium treatment
Number of subjects: 19
Study: 34531443

Group type: EXPERIMENTAL
Intervention: Collar Therapy Indicator (COTI) for monitoring radioactive iodine uptake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional methods of monitoring radioactive iodine uptake
Number of subjects: 0
Study: 34531537

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily
Number of subjects: 30
Study: 34531588

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR) T-cells
Number of subjects: 0
Study: 34531755

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment, specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34532363

Group type: EXPERIMENTAL
Intervention: Camrelizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 34532768

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transperineal laser ablation (TPLA)
Number of subjects: 44
Study: 34532852

Group type: EXPERIMENTAL
Intervention: Synthetic THC analogue (dronabinol, nabilone)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cannabinoids (including natural delta-9-tetrahydrocannabinol)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 34533416

Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath-Hold (DIBH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Free Breathing (FB)
Number of subjects: 10
Study: 34533464

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: User acceptance testing
Number of subjects: 70
Study: 34533472

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibodies measured in saliva
Number of subjects: 1850

Group type: COMPARATOR
Intervention: Adult comparator group
Number of subjects: 1850

Group type: COMPARATOR
Intervention: Adult validation group
Number of subjects: 1850
Study: 34533644

Group type: EXPERIMENTAL
Intervention: NIV-NAVA with NAVA levels progressively increased starting from 0.5 cmH2O
Number of subjects: 0
Study: 34533656

Group type: EXPERIMENTAL
Intervention: Objective measures of socioeconomic status (SES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective social class (SSC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated conceptual socioecological model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theoretical models connecting SES and SSC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical implications
Number of subjects: 0
Study: 34533772

Group type: EXPERIMENTAL
Intervention: Optimal PIF
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Suboptimal PIF
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: No inhalation technique errors
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Inhalation technique errors
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Adhering to medication
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Not adhering to medication
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: PIF measurements, inhalation technique, medication adherence
Number of subjects: 1200
Study: 34534131

Group type: EXPERIMENTAL
Intervention: REAnimation Low Immune Status Marker immunomonitoring panel
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Combined monitoring of pro-/anti-inflammatory, innate, and adaptive immune responses
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Initial adaptive immune response
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Persistence of profound immune alterations
Number of subjects: 353
Study: 34534134

Group type: EXPERIMENTAL
Intervention: BMI threshold for arm circumference ≤26 cm
Number of subjects: 11585

Group type: EXPERIMENTAL
Intervention: BMI threshold for arm circumference ≤34 cm
Number of subjects: 11585

Group type: EXPERIMENTAL
Intervention: BMI threshold for arm circumference ≤44 cm
Number of subjects: 11585

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of BMI for predicting arm circumference
Number of subjects: 11585
Study: 34534157

Group type: EXPERIMENTAL
Intervention: Hearing aid amplification
Number of subjects: 42
Study: 34534180

Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All patients with migraine
Number of subjects: 150
Study: 34534188

Group type: EXPERIMENTAL
Intervention: Digital Health Intervention (DHI) consisting of a smartphone application, smartwatch, and wireless blood pressure monitor, costing $2750 per patient.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care alone.
Number of subjects: 0
Study: 34534199

Group type: EXPERIMENTAL
Intervention: OAB-V8 Questionnaire
Number of subjects: 124
Study: 34534223

Group type: EXPERIMENTAL
Intervention: SL-RNA detection in blood
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SL-RNA detection in CSF
Number of subjects: 97

Group type: COMPARATOR
Intervention: Combined trypanosome detection in lymph and blood
Number of subjects: 97
Study: 34534280

Group type: EXPERIMENTAL
Intervention: α-ketoglutaric acid elevation at day + 100 (D100) and at the onset of cGVHD
Number of subjects: 222

Group type: COMPARATOR
Intervention: Metabolomic patterns at D100
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Metabolomic correlation patterns with clinical presentation
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: α-ketoglutaric acid as a metabolomic biomarker
Number of subjects: 222
Study: 34534337

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided high-intensity focused ultrasound neurotomy
Number of subjects: 10
Study: 34534421

Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Antipsychotic Medication plus Customized Adherence Enhancement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34534430

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (6.4 mg per kilogram of body weight)
Number of subjects: 91
Study: 34534514

Group type: EXPERIMENTAL
Intervention: Acalabrutinib, venetoclax, and obinutuzumab
Number of subjects: 37
Study: 34534722

Group type: EXPERIMENTAL
Intervention: A fumigatus sensitization (positive skin prick test or specific IgE)
Number of subjects: 318

Group type: COMPARATOR
Intervention: A fumigatus nonsensitized subjects
Number of subjects: 318
Study: 34535102

Group type: EXPERIMENTAL
Intervention: Interdental papilla biopsy protocol
Number of subjects: 148
Study: 34535275

Group type: EXPERIMENTAL
Intervention: Changes to departmental strategies for airway management
Number of subjects: 3786
Study: 34535360

Group type: EXPERIMENTAL
Intervention: Initial insulin therapy for ≥3 months
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Higher baseline HbA1c (>8%)
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Smaller difference between baseline and target HbA1c levels
Number of subjects: 1194
Study: 34535471

Group type: EXPERIMENTAL
Intervention: Intraoperative skeletal muscle tissue oxygenation (SmO2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hsTnT) measured preoperatively and on the first and second day after surgery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Skeletal cerebral tissue oxygenation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MINS and ICU admission within 30 days
Number of subjects: 70
Study: 34535487

Group type: EXPERIMENTAL
Intervention: General Practitioner (GP)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Physiotherapist (PT)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Chiropractor (C)
Number of subjects: 452
Study: 34535796

Group type: EXPERIMENTAL
Intervention: COVID-19-positive patients during the pandemic
Number of subjects: 5307

Group type: EXPERIMENTAL
Intervention: COVID-19-negative patients during the pandemic
Number of subjects: 5307

Group type: COMPARATOR
Intervention: COVID-19-negative patients prepandemic
Number of subjects: 5307
Study: 34536305

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study: 34536405

Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec gene therapy (1·1×10^14 vg/kg) administered as a one-time intravenous infusion.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (untreated patients in the PNCR cohort).
Number of subjects: 33
Study: 34536990

Group type: EXPERIMENTAL
Intervention: sVHD (significant valvular heart disease)
Number of subjects: 983
Study: 34537845

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 120
Study: 34538132

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34538257

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg every 2 weeks or every 4 weeks)
Number of subjects: 341
Study: 34538260

Group type: EXPERIMENTAL
Intervention: SPG5 patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Measurement of SCA on T9
Number of subjects: 17
Study: 34538263

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (37 participants)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (35 participants)
Number of subjects: 72
Study: 34538625

Group type: EXPERIMENTAL
Intervention: Echocardiographic phenotypes identified using the e'VM algorithm
Number of subjects: 827
Study: 34538630

Group type: EXPERIMENTAL
Intervention: Coronary CTA with CT-MPI
Number of subjects: 132

Group type: COMPARATOR
Intervention: Coronary CTA alone
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Absolute MBF
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Relative MBF
Number of subjects: 132
Study: 34539356

Group type: EXPERIMENTAL
Intervention: CT38s at an infusion rate of 0.03 μg/kg/h
Number of subjects: 0